Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Amgen is a global biotechnology pioneer operating in a single segment: human therapeutics. The company discovers, develops, manufactures, and delivers innovative medicines for serious diseases, with a robust pipeline including potential first-in-class medicines. The company operates in approximately 100 countries.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $36.75 billion | $33.42 billion | +10% |
| Product Sales | $35.15 billion | $32.03 billion | +10% |
| Operating Income | $9.08 billion | $7.26 billion | +25% |
| Net Income | $7.71 billion | $4.09 billion | +89% |
| Diluted EPS | $14.23 | $7.56 | +88% |
| Operating Cash Flow | $9.96 billion | $11.49 billion | -13% |
| Capital Expenditures | $1.86 billion | $1.10 billion | +69% |
| Total Debt (Carrying Value) | $54.60 billion | $60.10 billion | -9% |
| Cash and Cash Equivalents | $9.13 billion | $11.97 billion | -24% |
Margin Analysis: Operating margin improved to 24.7% in 2025 from 21.7% in 2024. Cost of sales decreased to 32.8% of total revenues, driven by lower amortization of acquisition-related assets and manufacturing costs.
Material Changes vs. Prior Period
- Revenue Growth: Total product sales increased 10%, driven by 13% volume growth partially offset by a 3% decline in net selling price. U.S. volume grew 13% and Rest of World (ROW) volume grew 14%.
- Profitability Surge: Net income nearly doubled (+89%) primarily due to a significant increase in "Other income, net" ($2.65 billion vs. $0.51 billion in 2024), driven by net unrealized gains on equity investments (primarily BeOne) compared to losses in the prior year.
- Debt Reduction: The company retired $6.0 billion of debt in 2025, consisting of $5.0 billion in repayments and $1.0 billion in repurchases, resulting in a $264 million gain on extinguishment.
- Impairment Charges: Operating expenses included $1.2 billion in intangible asset impairment charges related to Otezla due to CMS Medicare price setting selections.
- R&D Investment: R&D expenses increased 22% to $7.27 billion, driven by investments in Later-Stage Clinical Programs, including MariTide.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2026 Expectations: Management expects volume growth from certain brands to be partially offset by net selling price declines. First-quarter sales are historically lower due to plan changes and insurance reverifications.
- Dividends: The quarterly cash dividend was increased by 6% to $2.38 per share in 2025. A dividend of $2.52 per share was declared for Q1 2026.
- Capital Allocation: The company continues to invest in manufacturing expansion (North Carolina, Ohio, Puerto Rico) and R&D while returning capital via dividends and maintaining a $6.8 billion stock repurchase authorization.
Key Risks and Contingencies
- Patent Expirations and Biosimilars: Patents for Prolia and XGEVA expired in the U.S. in February 2025 and in select European countries in November 2025. Management expects accelerated sales erosion in 2026 due to biosimilar competition.
- Regulatory and Pricing Pressures:
- Medicare Price Setting: ENBREL is subject to Medicare price setting starting January 1, 2026, and Otezla starting January 1, 2027, expected to negatively impact profitability.
- MFN Pricing: The company announced actions satisfying the Administration's Most-Favored-Nations (MFN) pricing requests, though ultimate effects on net sales remain uncertain.
- Product-Specific Issues:
- TAVNEOS: The FDA requested voluntary withdrawal of TAVNEOS in January 2026 due to concerns over clinical trial adjudication and hepatotoxicity. Amgen declined to withdraw, citing confidence in the benefit-risk profile, and is evaluating next steps.
- Repatha: FDA broadened approval in August 2025 to include adults at increased risk for cardiovascular events without prior diagnosis, supported by positive Phase 3 VESALIUS-CV trial results.
- Tax Litigation: Amgen is contesting IRS Notices of Deficiency for tax years 2010-2015 regarding profit allocation between the U.S. and Puerto Rico. A decision from the U.S. Tax Court is expected no earlier than the second half of 2026. Potential additional tax liabilities could be substantial.
- Antitrust Litigation: A jury awarded Regeneron $406.8 million in damages in an antitrust case regarding Repatha sales practices. Amgen has not recorded a liability, deeming a loss not probable, but the outcome remains uncertain pending post-trial motions and appeals.
Investor Verification Checklist
- Biosimilar Impact: Verify the actual sales erosion trajectory for Prolia and XGEVA in 2026 as multiple biosimilars launch.
- Medicare Price Setting: Monitor the specific price reductions mandated by CMS for ENBREL (2026) and Otezla (2027) and their impact on net revenue.
- TAVNEOS Resolution: Track the outcome of the FDA regulatory process regarding TAVNEOS, as a forced withdrawal could trigger significant intangible asset impairments.
- Tax Court Outcome: Assess the final ruling on the IRS tax dispute (2010-2015), which could result in billions in additional tax liabilities.
- Antitrust Appeal: Review the status of the Regeneron antitrust appeal and potential for trebled damages or injunctive relief.
- MariTide Pipeline: Monitor Phase 3 data readouts for MariTide (chronic weight management, cardiovascular disease) as a key growth driver.